Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR/Cas9 genome editing

M E Bogomiakova; E K Sekretova; A V Eremeev; L D Shuvalova; P A Bobrovsky; E A Zerkalenkova; O S Lebedeva; M A Lagarkova

doi:10.1016/j.scr.2021.102451

Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR/Cas9 genome editing

Stem Cell Res. 2021 Aug:55:102451. doi: 10.1016/j.scr.2021.102451. Epub 2021 Jun 30.

Authors

M E Bogomiakova¹, E K Sekretova², A V Eremeev³, L D Shuvalova², P A Bobrovsky⁴, E A Zerkalenkova⁵, O S Lebedeva⁴, M A Lagarkova²

Affiliations

¹ Federal State Budgetary Institution Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Malaya Pirogovskaya, 1a, 119435 Moscow, Russia; Lomonosov Moscow State University, GSP-1, Leninskie Gory, Moscow 119991, Russia; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Malaya Pirogovskaya, 1a, 119435 Moscow, Russia.
² Federal State Budgetary Institution Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Malaya Pirogovskaya, 1a, 119435 Moscow, Russia; Lomonosov Moscow State University, GSP-1, Leninskie Gory, Moscow 119991, Russia.
³ Federal State Budgetary Institution Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Malaya Pirogovskaya, 1a, 119435 Moscow, Russia; Koltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow 119334, Russia; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Malaya Pirogovskaya, 1a, 119435 Moscow, Russia. Electronic address: eremeev@yandex.ru.
⁴ Federal State Budgetary Institution Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Malaya Pirogovskaya, 1a, 119435 Moscow, Russia; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Malaya Pirogovskaya, 1a, 119435 Moscow, Russia.
⁵ Rogachev Federal Scientific and Clinical Centre of Pediatric Hematology Oncology and Immunology, 1 Samory Mashela str, 117997 Moscow, Russia.

PMID: 34237591
DOI: 10.1016/j.scr.2021.102451

Abstract

The mismatch of HLA haplotypes between donor and recipient adversely affects the outcome of tissue transplantation. TheB2Mgene knockout (B2M-KO) disrupts the HLA I heterodimer formation; therefore,B2M-KO cells have reduced immunogenicity to allogeneic CD8⁺ T cells. Thus, theB2M-KO IPSCs and their derivatives can potentially solve a problem of the immunological compatibility in allogeneic transplantations. Using CRISPR/Cas9-mediated genome editing, we generated a human B2M-KO iPSC line (RCPCMi007-A-1). The RCPCMi007-A-1 iPSCs express pluripotency markers, have typical stem cell morphology, maintain normal karyotype, and the ability to differentiate into three germ layers.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

CD8-Positive T-Lymphocytes
CRISPR-Cas Systems / genetics
Gene Editing*
Humans
Induced Pluripotent Stem Cells*